Compare AbbVie Inc (ABBV) vs LyondellBasell Industries NV (LYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs LyondellBasell Industries NV — how do they compare? AbbVie Inc trades at $249.99 (market cap $438.19B), while LyondellBasell Industries NV trades at $63.95 (market cap $20.24B). The key difference: AbbVie Inc is far larger — about 21.6× LyondellBasell Industries NV's market cap, and LyondellBasell Industries NV pays the higher dividend (6.58%). Which is the better fit depends on your goals.
| ABBV | LYB | |
|---|---|---|
Market Cap | $438.19B | $20.24B |
Sector | Health | Basic Materials |
52-Week High | $263.58 | $82.38 |
52-Week Low | $197.38 | $42.28 |
Enterprise Value | $502.45B | $31.83B |
Dividend Yield | 2.79% | 6.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.
Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.
LyondellBasell Industries (LYB) trades at $59.595, down 2.97% on the day, with a bearish technical signal. The company reported a strong Q2 2026 earnings beat ($4.30 EPS vs. $3.44 expected) but faces declining revenue and negative net income margins. Recent news highlights supply disruptions supporting margins, while analyst consensus is a Buy with a $70.56 price target, implying 18% upside.
Outlook is mixed: earnings momentum and undervaluation (P/S 0.62) offer opportunity, but weak profitability and high debt pose risks. The stock's direction hinges on margin sustainability and broader economic conditions affecting chemical demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →
